Form 4: NanoVibronix Chief Medical Officer Acquires 10,000 Stock Options
SEC Form 4
Harold Jacob, Chief Medical Officer of NanoVibronix, Inc., acquired 10,000 stock options at an exercise price of $0.5995 on December 30, 2024.
Summary
- Harold Jacob, the Chief Medical Officer of NanoVibronix, Inc., has acquired 10,000 stock options.
- The options were granted on December 30, 2024, with an exercise price of $0.5995 per share.
- The options vest immediately and expire on December 30, 2034.
- The underlying security for these options is 10,000 shares of NanoVibronix common stock.
Sentiment
Score: 7
Explanation: The document reflects a routine executive compensation event, which is generally positive for aligning management with shareholder interests. It is not a major event, but it is a positive indicator of management's commitment.
Positives
- The grant of stock options to a key executive like the Chief Medical Officer can be seen as an incentive to align their interests with the company's success.
- The immediate vesting of the options suggests a strong commitment from the company to the executive.
Industry Context
This is a standard practice for companies to incentivize key executives with stock options, aligning their interests with the company's performance and shareholder value.
Comparison to Industry Standards
- Stock option grants are a common form of executive compensation across the biotechnology and medical device industries.
- The vesting schedule of these options, being immediate, is not uncommon for senior executives.
- Companies like Medtronic, Boston Scientific, and Stryker also use stock options as part of their executive compensation packages.
Stakeholder Impact
- The stock option grant could positively impact shareholder value if the executive's performance leads to company growth.
- The grant incentivizes the Chief Medical Officer to work towards the company's success.
Key Dates
| Date | Description |
|---|---|
| 12/30/2024 | Date of the stock option grant and vesting. |
| 01/02/2025 | Date of signature of the SEC Form 4. |
| 12/30/2034 | Expiration date of the stock options. |
Keywords
stock options, insider trading, executive compensation, NanoVibronix, NAOV, Harold Jacob, Chief Medical Officer
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.